EP3433622A4 - Ercc1 et autres marqueurs pour la stratification de patients atteints d'un cancer bronchique non à petites cellules - Google Patents

Ercc1 et autres marqueurs pour la stratification de patients atteints d'un cancer bronchique non à petites cellules Download PDF

Info

Publication number
EP3433622A4
EP3433622A4 EP17770875.7A EP17770875A EP3433622A4 EP 3433622 A4 EP3433622 A4 EP 3433622A4 EP 17770875 A EP17770875 A EP 17770875A EP 3433622 A4 EP3433622 A4 EP 3433622A4
Authority
EP
European Patent Office
Prior art keywords
bronchic
ercc1
stratification
markers
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17770875.7A
Other languages
German (de)
English (en)
Other versions
EP3433622A1 (fr
Inventor
Christina Yau
Fabiola CECCHI
Todd Hembrough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantomics LLC
Original Assignee
Nantomics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantomics LLC filed Critical Nantomics LLC
Publication of EP3433622A1 publication Critical patent/EP3433622A1/fr
Publication of EP3433622A4 publication Critical patent/EP3433622A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
EP17770875.7A 2016-03-21 2017-03-17 Ercc1 et autres marqueurs pour la stratification de patients atteints d'un cancer bronchique non à petites cellules Withdrawn EP3433622A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662311368P 2016-03-21 2016-03-21
US201662337209P 2016-05-16 2016-05-16
PCT/US2017/023080 WO2017165240A1 (fr) 2016-03-21 2017-03-17 Ercc1 et autres marqueurs pour la stratification de patients atteints d'un cancer bronchique non à petites cellules

Publications (2)

Publication Number Publication Date
EP3433622A1 EP3433622A1 (fr) 2019-01-30
EP3433622A4 true EP3433622A4 (fr) 2019-11-13

Family

ID=59900771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17770875.7A Withdrawn EP3433622A4 (fr) 2016-03-21 2017-03-17 Ercc1 et autres marqueurs pour la stratification de patients atteints d'un cancer bronchique non à petites cellules

Country Status (7)

Country Link
EP (1) EP3433622A4 (fr)
JP (1) JP2019513982A (fr)
CN (1) CN109844539A (fr)
AU (1) AU2017236791B2 (fr)
CA (1) CA3016340A1 (fr)
IL (1) IL261537A (fr)
WO (1) WO2017165240A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2684606C1 (ru) * 2017-11-29 2019-04-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СибГМУ Минздрава России) Способ комбинированного лечения немелкоклеточного рака легкого
CN113970638B (zh) 2021-10-24 2023-02-03 清华大学 确定胃癌极早期发生风险及评估胃癌前病变进展风险的分子标志及其在诊断试剂盒中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518416B1 (en) * 2000-12-01 2003-02-11 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
EP1835285A1 (fr) * 2006-03-14 2007-09-19 Institut Gustave Roussy Expression ERCC1 dans la prédiction de la réponse à une chimiothérapie du cancer
WO2011109806A2 (fr) * 2010-03-05 2011-09-09 On-Q-ity Biomarqueurs pour l'identification, la surveillance et le traitement du cancer bronchopulmonaire non à petites cellules
US20120289592A1 (en) * 2011-05-13 2012-11-15 University Of Southern California Ercc1 gene expression level is associated with clinical outcomes in esophageal cancer patients
GB201316024D0 (en) * 2013-09-09 2013-10-23 Almac Diagnostics Ltd Molecular diagnostic test for lung cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MARIE WISLEZ ET AL: "Customized Adjuvant Phase II Trial in Patients With Non-Small-Cell Lung Cancer: IFCT-0801 TASTE", JOURNAL OF CLINICAL ONCOLOGY, vol. 32, no. 12, 20 April 2014 (2014-04-20), US, pages 1256 - 1261, XP055625891, ISSN: 0732-183X, DOI: 10.1200/JCO.2013.53.1525 *
OLAUSSEN K A ET AL: "DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy", THE NEW ENGLAND JOURNAL OF MEDICINE, - NEJM -, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 355, no. 10, 7 September 2006 (2006-09-07), pages 983 - 991, XP002612486, ISSN: 0028-4793, DOI: 10.1056/NEJMOA060570 *
See also references of WO2017165240A1 *
SORIA ET AL: "Abstract No. OA 06.05) Proteomic analysis of ERCC1 predict benefit of platinum therapy in NSCLC: A Reevaluation of samples from the TASTE trial", JOURNAL OF THORACIC ONCOLOGY, vol. 12, 1 January 2017 (2017-01-01), pages s265 - s266, XP055424167 *

Also Published As

Publication number Publication date
AU2017236791B2 (en) 2020-07-02
WO2017165240A1 (fr) 2017-09-28
AU2017236791A1 (en) 2018-09-13
EP3433622A1 (fr) 2019-01-30
IL261537A (en) 2018-10-31
CA3016340A1 (fr) 2017-09-28
JP2019513982A (ja) 2019-05-30
CN109844539A (zh) 2019-06-04

Similar Documents

Publication Publication Date Title
EP3242930A4 (fr) Culture cellulaire microfluidique de sphéroïdes de cellules tumorales dérivées de patient
MA43719A (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et d'autres cancers
DK3849534T3 (da) Kombination af dasatinib og adagrasib til anvendelse i behandling af ikke-småcellet lungecancer
IL262245A (en) Methods and kits for diagnosing and assessing risk for patients with ischemia
EP3635108A4 (fr) Agents d'activation destinés à la transfection de cellules et/ou la production de vecteur raav améliorées
EP3350313A4 (fr) Dérivation d'organoïdes hépatiques à partir de cellules souches pluripotentes humaines
EP3693054C0 (fr) Réduction de la motilité de cellules cancéreuses à l'aide de champs de traitement de tumeurs (ttfields)
IL248299B (en) A method and kit for determining the tissue or cell origin of dna
EP2994530A4 (fr) Modification protéique de cellules vivantes à l'aide de sortase
EP3371301A4 (fr) Procédés et compositions pour induire la différenciation de cellules hématopoïétiques
EP3400013A4 (fr) Anticorps spécifiques pour la cadhérine-17 et cellules cytotoxiques pour le traitement du cancer
DK3142751T3 (da) Anti-B7-H1- og anti-CTLA-4-antistoffer til behandling af ikke-småcellet lungecancer
FR3059009B1 (fr) Microcompartiment cellulaire et procedes de preparation
EP3408372A4 (fr) Aliquotage microfluidique pour l'isolement de cellules individuelles
MA52542A (fr) Thérapie cellulaire adoptive
EP3341027A4 (fr) Complexes de transfection et leurs procédés d'utilisation
SG11202005063XA (en) NOVEL MULTI-ORGAN-CHIPS ESTABLISHING DIFFERENTIATION OF iPSC-DERIVED CELLS INTO ORGAN EQUIVALENTS
IL280603A (en) Discovery of nucleic acids in vitro
EP3386986A4 (fr) Conjugués porphyrine d'or-peg et procédés d'utilisation
DK3386523T3 (da) Bifidobacterium longum til behandling af fedme og associerede metabolske sygdomme
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation
IL263687A (en) Phospholipid ether analogs for the identification and isolation of circulating tumor cells
EP3347449A4 (fr) Procédés d'expansion de cellules et compositions thérapeutiques
EP3489936A4 (fr) Corps d'affichage
IL290297A (en) Modified cytotoxic t cells and methods of use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180829

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191016

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20191010BHEP

Ipc: G01N 33/574 20060101ALI20191010BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20200722